Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis

European Journal of Gastroenterology and Hepatology

Volumn 14, Issue 10, 2002, Pages 1101-1111

  Sikes, David H ^a   Agrawal, Naurang M ^a   Zhao, William W ^a   Kent, Jeffrey D ^a   Recker, David P ^a   Verburg, Kenneth M ^a  

^a PFIZER INC   (United States)

Author keywords

COX 2 specific inhibitors; Cyclo oxygenase; Diclofenac; Gastroduodenal ulcers; Ibuprofen; Nonsteroidal anti inflammatory drugs; Osteoarthritis; Valdecoxib

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; VALDECOXIB;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOSCOPY; FEMALE; GASTRODUODENAL ULCER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; DICLOFENAC; DOUBLE-BLIND METHOD; DUODENAL ULCER; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IBUPROFEN; ISOENZYMES; ISOXAZOLES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OSTEOARTHRITIS; PEPTIC ULCER; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; STOMACH ULCER; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0036794967     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200210000-00011     Document Type: Article

References (50)

1. Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy. Recognition and response. Arch Intern Med 1987; 147:2093-2100.
2. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 18:6-10.
3. Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with non-steroidal anti-inflammatory drugs. Lancet 1994; 343:769-772.
4. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345:433-442.
5. Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D, et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA 1994; 91:11202-11206.
6. Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koboldt CM, Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2-specific inhibitors. J Biol Chem 1996; 271:15810-15814.
7. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91:3228-3232.
8. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74:1095-1105.
9. Saag K, van der Heijde D, Fisher C, Samar A, DeTora L, Bolognese J, et al. Rofecoxib, a new COX-2 inhibitor, shows sustained efficacy, comparable with other NSAIDs: a 6-week and a 1-year trial in patients with OA. Osteoarthritis Studies Group. Arch Fam Med 2000; 9:1124-1134.
10. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of UGI ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95:1681-1690.
11. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis - The CLASS study: a randomized controlled trial. JAMA 2000; 284:1247-1255.
12. Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzensulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000; 43:775-777.
13. Lanza FL, Royer GL Jr, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980; 303:136-138.
14. Cooperating Clinics Committee of American Rheumatism Association. A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 1965; 8:302-334.
15. Emery P, Zeider H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354:2106-2111.
16. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis - a randomized controlled trial. JAMA 1999; 282:1921-1928.
17. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, Van de Putte LBA. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000; 43:4-13.
18. Simon LS. Nonsteroidal antiinflammatory drugs and their effects. The importance of COX 'selectivity'. J Clin Rheumatol 1996; 2:135-140.
19. Verburg KM, Maziasz TJ, Weiner E, Loose L, Geis GS, Isakson PC. COX-2-specific inhibitors: definition of a new therapeutic concept. Am J Ther 2001; 8:49-64.
20. Hawkey CJ. The gastroenterologist's caseload: contribution of the rheumatologist. Semin Arthritis Rheum 1997; 26(Suppl 1):11-15.
21. Agrawal NM, Van Kerckhove HEJM, Erhardt LJ, Geis GS. Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. Dig Dis Sci 1995; 40:1125-1131.
22. Roth SH, Bennett RE, Caldron PH. Endoscopic evaluation of the long term effects of diclofenac sodium and naproxen in elderly patients with arthritis. Clin Drug Invest 1995; 9:171-179.
23. Roth SH, Bennett R, Caldron P. Five-year comparative endoscopic evaluation of arthritis patients treated with nabumetone versus naproxen. Arthritis Rheum 1991; 34(Suppl):S157.
24. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. N Engl J Med 1996; 334:1435-1439.
25. Geis GS, Stead H, Wallemark CB, Nicholson PA. Prevalence of mucosal lesions in the stomach anal duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac-associated lesions. J Rheumatol 1991; 18(Suppl 28):11-14.
26. Roth SH, Tindall EA, Jain AK, McMahon FG, April PA, Bockow BI, et al. A controlled study comparing the effects of nabumetone, ibuprofen and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993; 153:2565-2571.
27. Cheatum DE, Arvanitakis C, Gumpel M, Stead H, Geis GS. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther 1999; 21:992-1003.
28. Langman MJS. Epidemiologic evidence on the association between peptic ulceration anal anti-inflammatory drug use. Gastroenterology 1989; 96:640-646.
29. MacDonald TM, Morant SV, Robinson GC, Shield M J, McGilchrist MM, Murray FE, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315:1333-1337.
30. Harris SI, Kuss M, Hubbard RC, Goldstein JL. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 2001; 23:1422-1428.
31. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary safety and efficacy of SC-58635, a novel COX-2 inhibitor. Arthritis Rheum 1998; 41:1591-1602.
32. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RH, Verburg KM, Geis GS. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase inhibitor compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96:1019-1027.
33. Akdamar K, Ertan A, Agrawal NM, McMahon FG, Ryan J. Upper gastrointestinal endoscopy in normal asymptomatic volunteers. Gastrointest Endosc 1986; 32:78-80.
34. Ihmaki T, Varis K, Siurala M. Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Scand J Gastroenterol 1979; 14:801-812.
35. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer disease. BMJ 1995; 310:827-830.
36. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348:1413-1416.
37. Graham DY. NSAIDs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol 1996; 10:2080-2086.
38. Kanji S, Dumo P. The effect of Helicobacter pylori eradication on NSAID-induced gastrointestinal toxicity. Ann Pharmacother 2001; 35:249-254.
39. Bazzoli F, De Luca L, Graham DY, Helicobacter pylori infection and the use of NSAIDs. Best Pract Res Clin Gastroenterol 2001; 15:775-785.
40. Dobrilla G, Benvenuti S, de Guelmi A. The epidemiology of the gastroduodenal damage induced by aspirin and other nonsteroidal anti-inflammatory drugs. Recent Prog Med 1997; 88:202-211.
41. Hansen JM, Hallas J, Lauritsen JM, Bytzer P. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making, Scand J Gastroenterol 1996; 31:126-130.
42. Siegle I, Klein T, Backman JT, Saal JG, Nusing RM, Fritz P. Expression of cyclooxygenase 1 anal cyclooxygenase 2 in human synovial tissue. Arthritis Rheum 1998; 41:122-129.
43. Roth SH. NSAID gastropathy: a new understanding. Arch Intern Med 1996; 156:1623-1628.
44. Huang J, Hunt RH. A clinician's view of strategies for preventing NSAID-induced gastrointestinal ulcers. Inflammopharmacology 1996; 4:17-30.
45. Bradley JD, Brandt KD, Katz BP, Kalinasinski LA, Ryan SI. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with OA of the knee. N Engl J Med 1991; 325:87-91.
46. Parr G, Darekar B, Fletcher A, Bulpitt CJ. Joint pain and quality of life: results of a randomized trial. Br J Clin Pharmacol 1989; 27:235-242.
47. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ, et al. Gastrointestinal tolerability of the cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000; 160:2998-3003.
48. Shoen RT, Vender RJ. Mechanisms of nonsteroidal antiinflammatory drug-induced gastric damage. Am J Med 1989; 86:449-458.
49. Barrier CH, Hirschowitz BI. Controversies in the detection and management of nonsteroidal antiinflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum 1989; 32:926-932.
50. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106:13S-24S.